Breaking Down Organogenesis Holdings Inc.’s Q4 Earnings Report
Organogenesis Holdings Inc. (NASDAQ: ORGO) unveiled its Q4 earnings report on February 29, 2024, marking a significant moment for the company. Let’s delve into the key takeaways from the announcement:
Earnings: Despite falling short of estimated earnings by 0.0%, Organogenesis reported an EPS of $0.01, matching up closely with expectations.
Revenue: The company faced a decline in revenue amounting to $15.87 million compared to the same period last year, signaling a challenging quarter.
Past Performance: In the preceding quarter, Organogenesis surpassed EPS estimates by $0.04, triggering an impressive 11.0% surge in share price the following day, showcasing the company’s potential.
Analyzing previous quarters provides further insights into Organogenesis’ financial trajectory:
Quarter EPS Est. EPS Actual Rev Est. Rev Actual
Q3 2023 $0.00 $0.04 $111.40M $108.53M
Q2 2023 $0.02 $0.05 $115.10M $117.32M
Q1 2023 -$0.02 -$0.01 $95.50M $107.64M
Q4 2022 $0.05 $0.07 $122.40M $115.52M
For further details on Organogenesis Holdings Inc.’s earnings performance, interested parties can explore their investor relations page for comprehensive information.
This summary has been crafted using a blend of insights from various reputable sources, including Benzinga, Nasdaq, TipRanks, and Yahoo Finance, to provide a comprehensive overview of the company’s financial standing.
ORGO Stock Analysis: Promising Performance on February 29, 2024
On February 29, 2024, ORGO stock showed promising performances as it traded in the middle of its 52-week range and above its 200-day simple moving average. This indicates that the stock has been relatively stable and potentially has room for growth.
The price of ORGO shares increased by $0.08 since the market last closed, representing a 2.29% rise. This positive price momentum is a good sign for investors who are looking for opportunities to capitalize on potential gains in the stock market.
Overall, ORGO stock showed positive price momentum on February 29, 2024, with a modest increase in share price during regular trading hours. Investors should continue to monitor the stock’s performance in the coming days to see if this positive trend continues or if there are any potential challenges that may impact its value.
ORGO Stock Financial Performance Declines in 2024: Revenue, Net Income, and EPS Drop
On February 29, 2024, ORGO stock experienced a decline in its financial performance compared to the previous year and quarter. According to data from CNN Money, ORGO reported a total revenue of $450.89 million in the last year, which decreased by 3.67% since the previous year. In the third quarter of the same year, the total revenue dropped further to $108.53 million, representing a 7.49% decrease since the last quarter.
Similarly, ORGO’s net income also took a hit, with a reported net income of $15.53 million in the last year, marking an 83.63% decrease compared to the previous year. In the third quarter, the net income decreased to $3.17 million, reflecting a 40.43% decrease since the last quarter.
Furthermore, the earnings per share (EPS) of ORGO stock also saw a significant decline. The EPS was reported at $0.12 in the last year, indicating an 83.48% decrease since the previous year. In the third quarter, the EPS dropped to $0.02, showing a 40.75% decrease since the last quarter.
Overall, the financial performance of ORGO stock on February 29, 2024, showed a downward trend in total revenue, net income, and earnings per share. Investors and analysts may want to closely monitor the company’s future financial reports and strategies to assess its potential for growth and recovery in the market.
